{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:05:47Z","timestamp":1771020347733,"version":"3.50.1"},"reference-count":132,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Classical Hodgkin\u2019s lymphoma (cHL) accounts for 10% of all lymphoma diagnosis. The peculiar feature of the disease is the presence of large multinucleated Reed\u2013Sternberg and mononuclear Hodgkin cells interspersed with a reactive microenvironment (ME). Due to the production of a large number of cytokines, Hodgkin cells (HCs) and Hodgkin Reed\u2013Sternberg cells (HRSCs) attract and favour the expansion of different immune cell populations, modifying their functional status in order to receive prosurvival stimuli and to turn off the antitumour immune response. To this purpose HRSCs shape a biological niche by organizing the spatial distribution of cells in the ME. This review will highlight the contribution of the ME in the pathogenesis and prognosis of cHL and its role as a possible therapeutic target.<\/jats:p>","DOI":"10.3390\/cancers13143634","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T11:26:10Z","timestamp":1626780370000},"page":"3634","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma"],"prefix":"10.3390","volume":"13","author":[{"given":"Clara","family":"Bertuzzi","sequence":"first","affiliation":[{"name":"Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4136-3591","authenticated-orcid":false,"given":"Elena","family":"Sabattini","sequence":"additional","affiliation":[{"name":"Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Agostinelli","sequence":"additional","affiliation":[{"name":"Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/095952873201700106","article-title":"On some Morbid Appearances of the Absorbent Glands and Spleen","volume":"17","author":"Hodgkin","year":"1832","journal-title":"Med. Chir. Trans."},{"key":"ref_2","unstructured":"Swerdlow, S., Campo, E., and Harris, N. (2017). Classical Hodgkin lymphoma. Who Classification of Tumors of Haematopoietic and Lymphoid Tissues, IARC."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V97.2.496","article-title":"Down-regulation of BOB.1\/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription","volume":"97","author":"Stein","year":"2001","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAI.0b013e3181e79013","article-title":"Characterization of a new monoclonal antibody against PAX5\/BASP in 1525 paraffin-embedded human and animal tissue samples","volume":"18","author":"Agostinelli","year":"2010","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2004-09-3620","article-title":"Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas","volume":"106","author":"Mathas","year":"2005","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cancergencyto.2008.06.007","article-title":"BCL2 and BCL3 are recurrent translocation partners of the IGH locus","volume":"186","author":"Szymanowska","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature07969","article-title":"Frequent inactivation of A20 in B-cell lymphomas","volume":"459","author":"Kato","year":"2009","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/gcc.20789","article-title":"Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma","volume":"49","author":"Schmidt","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood.V99.4.1474","article-title":"Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma","volume":"99","author":"Gesk","year":"2002","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1056\/NEJMc0906731","article-title":"Long-term follow-up of survival in Hodgkin\u2019s lymphoma","volume":"361","author":"Canellos","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0000000000000168","article-title":"Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma","volume":"22","author":"Alperovich","year":"2016","journal-title":"Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)","volume":"124","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The classical Hodgkin\u2019s lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2009-10-247809","article-title":"Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond","volume":"115","author":"Aldinucci","year":"2010","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41375-020-0737-9","article-title":"PD-L1\/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma","volume":"34","author":"Kawashima","year":"2020","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Barros, M.H.M., Segges, P., Vera-Lozada, G., Hassan, R., and Niedobitek, G. (2015). Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124531"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"920898","DOI":"10.1155\/2011\/920898","article-title":"Pathobiology of hodgkin lymphoma","volume":"2011","author":"Piccaluga","year":"2011","journal-title":"Adv. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ijc.27314","article-title":"Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection","volume":"131","author":"Barros","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2017007260","article-title":"Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: Implications for immunotherapy","volume":"1","author":"Duffield","year":"2017","journal-title":"Blood Adv."},{"key":"ref_26","first-page":"S2152","article-title":"Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma","volume":"12","author":"Adam","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e23849","DOI":"10.4161\/onci.23849","article-title":"TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"OncoImmunology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5160565","DOI":"10.1155\/2019\/5160565","article-title":"Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer","volume":"2019","author":"Blessin","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(77)90281-1","article-title":"Reed-Sternberg-cell\/lymphocyte interaction","volume":"2","author":"Payne","year":"1977","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/path.1711220205","article-title":"Rosetting and other reactions of the Reed-Sternberg cell","volume":"122","author":"Stuart","year":"1977","journal-title":"J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: Increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-dependent secretion of galectin-1 by Reed\u2013Sternberg cells fosters immune privilege in classical Hodgkin lymphoma","volume":"104","author":"Ouyang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4 + regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1080\/10428194.2019.1636983","article-title":"Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment","volume":"60","author":"Ferrarini","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/bloodadvances.2018017244","article-title":"CXCR5 and ICOS expression identifies a CD8 T-cell subset with T FH features in Hodgkin lymphomas","volume":"2","author":"Le","year":"2018","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/1097-0142(19850715)56:2<333::AID-CNCR2820560222>3.0.CO;2-0","article-title":"Macrophage-histiocytes in Hodgkin\u2019s disease. The relationship of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease","volume":"56","author":"Ree","year":"1985","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: In Vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages survival in classic Hodgkin\u2019s lymphoma","volume":"62","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Guo, B., Cen, H., Tan, X., and Ke, Q. (2016). Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med., 14.","DOI":"10.1186\/s12916-016-0711-6"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000321567","article-title":"Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma","volume":"77","author":"Tzankov","year":"2010","journal-title":"Pathobiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00428-011-1140-8","article-title":"Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma","volume":"459","author":"Zaki","year":"2011","journal-title":"Virchows. Arch."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2010.031542","article-title":"Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin\u2019s lymphoma","volume":"96","author":"Kamper","year":"2011","journal-title":"Haematologica"},{"key":"ref_52","first-page":"733","article-title":"Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin\u2019s lymphoma","volume":"35","author":"Jakovic","year":"2012","journal-title":"Onkologie"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/10428194.2012.698274","article-title":"Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma","volume":"54","author":"Deau","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3324\/haematol.2019.243287","article-title":"Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP","volume":"106","author":"Jachimowicz","year":"2020","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Barros, M.H.M., Hauck, F., Dreyer, J.H., Kempkes, B., and Niedobitek, G. (2013). Macrophage polarisation: An immunohistochemical approach for identifying M1 and M2 macrophages. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080908"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2011-02-339911","article-title":"Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology","volume":"119","author":"Pello","year":"2012","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1038\/s41598-020-66010-z","article-title":"Tumor-associated macrophages in classical Hodgkin lymphoma: Hormetic relationship to outcome","volume":"10","author":"Werner","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/1878-0261.12616","article-title":"High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination","volume":"14","author":"Arlt","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2020.12.015","article-title":"Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma","volume":"500","author":"Casagrande","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-18-1133","article-title":"Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3K\u03b4\/\u03b3 inhibitor RP6530","volume":"25","author":"Locatelli","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cncr.11511","article-title":"A pilot study of rituximab in patients with recurrent, classic Hodgkin disease","volume":"98","author":"Younes","year":"2003","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2012-01-405456","article-title":"Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma","volume":"119","author":"Younes","year":"2012","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3109\/10428194.2014.951849","article-title":"High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages","volume":"56","author":"Panico","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1158\/0008-5472.CAN-05-3766","article-title":"Inhibitory effects of B cells on antitumor immunity","volume":"66","author":"Inoue","year":"2006","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccr.2005.04.014","article-title":"De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent","volume":"7","author":"Korets","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","article-title":"B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma","volume":"10","author":"Griss","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12282-018-0910-4","article-title":"Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer","volume":"26","author":"Ishigami","year":"2019","journal-title":"Breast Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/bjc.2013.493","article-title":"The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer","volume":"109","author":"Mohammed","year":"2013","journal-title":"J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ijc.30138","article-title":"Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer","volume":"139","author":"Berntsson","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13048-016-0232-0","article-title":"Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer","volume":"9","author":"Lundgren","year":"2016","journal-title":"J. Ovarian. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2013.01.036","article-title":"The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer","volume":"333","author":"Lohr","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjh.15703","article-title":"High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms","volume":"184","author":"Gholiha","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ajh.22168","article-title":"Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma","volume":"86","author":"Thompson","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature14395","article-title":"Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy","volume":"521","author":"Shalapour","year":"2015","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ccr.2014.04.026","article-title":"B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas","volume":"25","author":"Affara","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/jcp.37.5.519","article-title":"A quantitative study of mast cells in Hodgkin\u2019s disease","volume":"37","author":"Crocker","year":"1984","journal-title":"J. Clin. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0394632016644447","article-title":"Role of mast cells in fibrosis of classical Hodgkin lymphoma","volume":"29","author":"Nakayama","year":"2016","journal-title":"J. Immunopathol. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/leu.2012.81","article-title":"Mast cells promote the growth of Hodgkin\u2019s lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib","volume":"26","author":"Mizuno","year":"2012","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc2544","article-title":"A tense situation: Forcing tumour progression","volume":"9","author":"Butcher","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2249.2010.04190.x","article-title":"Transforming growth factor beta 1 plays an important role in inducing CD4(+)CD25(+)forhead box P3(+) regulatory T cells by mast cells","volume":"161","author":"Zhang","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1038\/onc.2010.348","article-title":"Mast cells have a protumorigenic role in human thyroid cancer","volume":"29","author":"Melillo","year":"2010","journal-title":"Oncogene"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000351145","article-title":"Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically","volume":"85","author":"Ammendola","year":"2013","journal-title":"Oncology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"703163","DOI":"10.1155\/2013\/703163","article-title":"Mast Cells Positive to Tryptase and c-Kit Receptor Expressing Cells Correlates with Angiogenesis in Gastric Cancer Patients Surgically Treated","volume":"2013","author":"Ammendola","year":"2013","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nm1649","article-title":"Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors","volume":"13","author":"Soucek","year":"2007","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.18632\/oncotarget.5467","article-title":"Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ER\u03b2\/CCL2\/CCR2 EMT\/MMP9 signals","volume":"7","author":"Rao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/DAD.0b013e31815c932a","article-title":"Mast cells have prognostic value in Merkel cell carcinoma","volume":"30","author":"Beer","year":"2008","journal-title":"Am. J. Dermatopathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood-2012-03-415638","article-title":"Mast cells play a protumorigenic role in primary cutaneous lymphoma","volume":"120","author":"Rabenhorst","year":"2012","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2353\/ajpath.2010.091286","article-title":"Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma","volume":"177","author":"Tripodo","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood-2013-04-497271","article-title":"Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma","volume":"123","author":"Franco","year":"2014","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bjc.6690070","article-title":"Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma","volume":"79","author":"Ribatti","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-007-9546-3","article-title":"Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: A study of 4444 cases","volume":"107","author":"Rajput","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ejh.12583","article-title":"Tumour-associated mast cells in classical Hodgkin\u2019s lymphoma: Correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome","volume":"96","author":"Andersen","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V83.8.2045.2045","article-title":"Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines","volume":"83","author":"Gruss","year":"1994","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1365-2141.2002.03768.x","article-title":"Mast cell infiltration correlates with poor prognosis in Hodgkin\u2019s lymphoma","volume":"119","author":"Molin","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"30523","DOI":"10.18632\/oncotarget.8864","article-title":"CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, In Vitro","volume":"7","author":"Hansen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/cclm-2013-0698","article-title":"Increased plasma arginase activity in human sepsis: Association with increased circulating neutrophils","volume":"52","author":"Darcy","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1479-5876-9-90","article-title":"Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines","volume":"9","author":"Lechner","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","article-title":"Arginase: An emerging key player in the mammalian immune system","volume":"158","author":"Munder","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/08820139.2012.680634","article-title":"Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: Mechanisms of T cell suppression and therapeutic perspectives","volume":"41","author":"Raber","year":"2012","journal-title":"Immunol. Invest."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1681s","DOI":"10.1093\/jn\/137.6.1681S","article-title":"Arginine and immunity","volume":"137","author":"Popovic","year":"2007","journal-title":"J. Nutr."},{"key":"ref_104","first-page":"1","article-title":"Analysis of myeloid suppressor marker arginase identifies CD68+\/arginase+ myeloid\/monocytic subsets and exerts stronger prognostic influence than macrophage quantification in classical Hodgkin lymphoma","volume":"98","author":"Gallamini","year":"2013","journal-title":"Haematologica"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13198","article-title":"Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy","volume":"168","author":"Romano","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"67333","DOI":"10.18632\/oncotarget.12024","article-title":"The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma","volume":"7","author":"Romano","year":"2016","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bjh.15801","article-title":"Immune off-target effects of Brentuximab Vedotin in relapsed\/refractory Hodgkin Lymphoma","volume":"185","author":"Romano","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Molgora, M., Cortez, V.S., and Colonna, M. (2021). Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy. Cancers, 13.","DOI":"10.3390\/cancers13040595"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/his.12458","article-title":"The role of the microenvironment in human immunodeficiency virus-associated classical Hodgkin lymphoma","volume":"65","author":"Koulis","year":"2014","journal-title":"Histopathology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/bloodadvances.2018030676","article-title":"Human peripheral blood DNAM-1 neg NK cells are a terminally differentiated subset with limited effector functions","volume":"3","author":"Stannard","year":"2019","journal-title":"Blood Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin Lymphoma with Reduced \u03b22M\/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/gene.2016.30","article-title":"CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse","volume":"17","author":"Razak","year":"2016","journal-title":"Genes. Immun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_115","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin\u2019s lymphoma: A retrospective, European, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet. Haematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): A multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet. Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","volume":"35","author":"Armand","year":"2021","journal-title":"Leukemia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation In Vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell."},{"key":"ref_128","first-page":"1209","article-title":"Expression of the immune checkpoint receptor TIGIT in Hodgkin\u2019s lymphoma","volume":"18","author":"Li","year":"2018","journal-title":"MC Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2004-10-4008","article-title":"Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma","volume":"105","author":"Willenbrock","year":"2005","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/iep.12128","article-title":"Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin\u2019s lymphoma: Correlation with MET expression","volume":"96","author":"Koh","year":"2015","journal-title":"Exp. Pathol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3324\/haematol.2011.056101","article-title":"Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Xu","year":"2012","journal-title":"Haematologica"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/14\/3634\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:32:19Z","timestamp":1760164339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/14\/3634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":132,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13143634"],"URL":"https:\/\/doi.org\/10.3390\/cancers13143634","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}